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Abstract Cardiotoxic side-effects of doxorubicin limit
the clinical use of this anti-cancer agent. Iron chelators
have been studied as protectors against doxorubicin-in-
duced cardiotoxicity. These iron chelators do not provide
optimal protection and have certain drawbacks. We there-
fore looked for new protectors and decided that these new
compounds should combine iron chelating and antioxidant
activity. Flavonoids appeared to possess those combined
iron chelating and antioxidant properties. Quantum chem-
ical evaluation of radical stabilization and determination of
physico-chemical properties of a series of flavonoids
brought our attention to the semi-synthetic flavonoid 7-
monohydroxyetylrutoside (monoHER). Both in vitro
(using an electrically paced mouse left atrium model) and
in vivo (using a mouse ECG telemetry model) experiments
corroborated the protective effect of monoHER. MonoHER
also showed anti-inflammatory properties. A subsequent
clinical phase I study showed that an i.v. dose of 1,500 mg/
m2 is a feasible and safe dose to be evaluated in a phase II
study to investigate the protective properties of monoHER
against doxorubicin-induced cardiotoxicity in cancer pa-
tients.
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Molecular mechanism of the cardiotoxicity
of doxorubicin
The clinical use of doxorubicin, a widely used anthracy-
cline is hampered by the common side-effects observed
upon use of the majority of anti-cancer agents, viz. bone
marrow suppression, alopecia, nausea and vomiting.
Doxorubicin-induced bone marrow suppression can now be
reduced by the use of haematopoietic growth factors. In
addition to these rather common acute toxicities, anthra-
cyclines contain the risk of causing a cardiomyopathy. In
fact, the development of cumulative dose-related cardio-
toxicity currently forms the major limitation of doxorubicin
use in the clinic.
The production of free radicals as by-product of doxo-
rubicin metabolism is considered to be the main mecha-
nism of doxorubicin-induced cardiotoxicity. The quinone
moiety of doxorubicin is converted into a semiquinone
form by the acquisition of one electron. This conversion
can occur either enzymatically or nonenzymatically. The
enzymatic reduction of the doxorubicin quinone ring is
performed by cytochrome P450 reductase, NADH dehy-
drogenase and cytochrome P450 [1]. The produced sem-
iquinone form is oxidized by molecular oxygen, which
yields back doxorubicin in its quinone form with con-
comitant production of superoxide anion radicals. This
process is called redox cycling. Superoxide radicals can
dismutate either enzymatically catalyzed by superoxide
dismutase or, albeit with a lower rate, spontaneously. From
this dismutation hydrogen peroxide is formed. This may
lead to toxicity. Iron ions have been suggested to play a
crucial role in this process. Not only because iron reacts
with hydrogen peroxide to form the reactive hydroxyl
radical but also because Fe3+ may form complexes with
doxorubicin. The theory on the iron-dependent formation
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of free radicals by doxorubicin semiquinones is supposed
to be the most prevailing one to explain the cardiotoxicity.
An internal electron shift may give reduction of iron, which
subsequently delivers this electron to molecular oxygen
yielding superoxide anion radicals.
The need for new protectors
Iron chelators have been studied as protectors against
doxorubicin-induced cardiotoxicity. The bispiperazinedi-
one ICRF 187 has been studied extensively. ICRF 187 is
also known as dexrazoxane and is the more water soluble
(+)enantiomorph of the racemic mixture ICRF-159, which
was originally developed as a conventional antineoplastic
agent [2]. In phase I trials using a variety of schedules in
both adults and children, dose-limiting toxicities on most
schedules were myelosuppression, except in children, in
whom the major dose-limiting toxicity was hepatotoxicity
[3]. In addition, research conducted at the same time as the
initial phase I studies showed that the divalent chelating
properties of ICRF-159 and 187 could protect animals from
the cardiotoxicity induced by anthracyclines [4, 5]. This
further corroborated the catalytic toxic role of iron ions in
the doxorubicin-induced cardiotoxicity. There are several
disadvantages associated with the use of ICRF-187. ICRF-
187 exerts a dose-dependent myelosuppression, which may
limit its addition to chemotherapy. Moreover, controversy
exists as to whether ICRF-187 decreases the antitumour
activity of doxorubicin. ICRF-187 is a prodrug which re-
quires hydrolysis to achieve the active form. Finally, ICRF-
198, the hydrolyzed form of ICRF-187 is an EDTA-like
chelator. This implies that because of stoichiometrical
restrictions the drug lacks the ability to occupy all six
coordination sites of iron. Consequently, iron remains
catalytically active to generate oxygen radicals. Besides
iron chelators as ICRF-187 and for example deferoxamine,
many other compounds have been evaluated for their po-
tential to reduce doxorubicin-induced cardiotoxicity, based
on a perceived ability to modulate some of the biochemical
alterations that accompany doxorubicin administration.
The list of compounds includes adenosine, anti-histamine
agents (both H1 and H2 blockers), beta-adrenoceptor
antagonists, amrinone, milrinone, fructose-1,6-diphos-
phate, inosine, ibuprofen, dextran, methylprednisone, salts
of bismuth, zinc and calcium, tetracycline antibiotics and a
number of iron chelators as deferoxamine, ICRF-187. In
addition, various antioxidants have been applied as vitamin
E, curcumin, lipoic acid and venoruton.
In view of the suggested molecular mechanism involved
in doxorubicin-induced cardiotoxicity we searched for
protectors which combine iron-chelating and oxygen radi-
cal scavenging properties. Moreover, the novel protector
should not interfere with the cytostatic activity of doxo-
rubicin.
The choice for flavonoids
A large series of flavonoids from several subclasses were
screened by quantum chemical calculation (Fig. 1) and
physico-chemical characterization to find antioxidants with
both iron chelating and oxygen radical scavenging prop-
erties [6–8]. To study the direct antioxidant action of the
flavonoids, the compounds were tested in the iron-inde-
pendent liver microsomal lipid peroxidation, which was
induced with azobisamidinopropane (ABAP), a hydrophilic
azo-initiator. ABAP generates a constant radical flow in the
water phase of the lipid peroxidation system. An excess of
EDTA was added to inactivate all traces of iron. A good
correlation was found between the inhibition (pIC50-value)
of the ABAP-induced lipid peroxidation by the flavonoids
and their half-peak oxidation potential (Ep/2) (Fig. 2). In
contrast to the ABAP-induced lipid peroxidation where
iron does not play a role in the initiation of lipid peroxi-
dation, iron is strongly involved in the lipid peroxidation
Fig. 1 Spin distribution of the quercetine and taxifoline radical.
Small changes in the molecule (in this case a 2–3 double bond) lead to
variation in the spin distribution and to changes in the antioxidant
activity of the molecule
Cardiovasc Toxicol (2007) 7:154–159 155
induced with Fe2+/ascorbic acid. Also in the enzymatic
doxorubicin induced lipid peroxidation iron is suggested to
play a role. The correlations of the inhibition of the lipid
peroxidation processes in which iron is involved are
weaker than the correlation obtained in the iron-indepen-
dent lipid peroxidation process (Fig. 2). This suggests that
besides the direct radical scavenging effect also the iron
chelating effect of the flavonoids is involved in their anti-
oxidant action.
Protection against negative inotropic action ex vivo
and in vitro
We subsequently tested a selection of promising flavonoids
which possess combined antioxidant and iron-chelating
properties in a series of in vitro and ex vivo organ bath
studies [9–11]. The flavonoid 7-monohydroxyethylrutoside
was able to protect almost completely (93%) against the
negative inotropic effect of 30 lM doxorubicin. This
concentration of doxorubicin gives 50% inhibition of the
inotropy of the isolated electrically paced mouse left atrium
(Fig. 3).
Protection against in vivo changes induced by
doxorubicin in the ECG of mice
The promising protector 7-monohydroxyethylrutoside was
further evaluated in vivo in a comparative study with
ICRF-187. Balb/c mice of 20–25 g were equipped with a
telemeter to measure ECG (Fig. 4). They were given 6 i.v.
doses of doxorubicin (4 mg/kg) at weekly intervals. ICRF-
187 (50 mg/kg) or 7-monohydroxyethylrutoside at 100,
250 or 500 mg/kg were given i.p. 1 h prior to doxorubicin
administration [12, 13]. A saline and a 7-monohydroxy-
ethylrutoside treated group served as control. At the end of
the study (week 8) the ST-interval of the ECG had in-
creased by 16.7 ± 2.7 ms (mean ± s.e. mean) in the
doxorubicin-treated mice. At the same time, the ST interval
had increased by only 1.8 ± 0.9 ms in ICRF-187 co-med-
icated mice and in 7-monohydroxyethylrutoside co-medi-
cated mice by only 7.8 ± 1.7 ms, 4.6 ± 0.7 ms,
1.7 ± 0.8 ms for 100, 250 and 500 mg/kg, respectively.
The ECG of the control animals did not change during the
study. The QRS complex did not change in either group
(Fig. 4).
Lack of interference with the tumour growth
inhibition in vitro and in vivo
Three cell lines were used i.e. the human ovarian cell lines
A2780 and OVCAR-3 and the human breast cancer cell
line MCF-7 to check for the effect of the selected flavonoid
7-monohydroxyethylrutoside on the IC50 values of growth
inhibition by doxorubicin (Table 1). A2780 cells were
approximately 10-fold more sensitive to doxorubicin than
MCF-7 and OVCAR-3 cells as measured from the IC50
values of 2.05 · 10–8, 2.09 · 10–7 and 3.28 · 10–7 M,
respectively. The compound 7-monohydroxyethylrutoside
was not cytotoxic at concentrations of 50 and 100 lM
(Table 1). More importantly, 7-monohydroxyethylrutoside
Fig. 2 Correlation between inhibition (pIC50-value) of ABAP-
induced lipid peroxidation by several flavonoids and their half-peak
oxidation potential. Lipid peroxidation was induced in mouse liver
microsomes with 10 mmol/l ABAP in the presence of 100 lmol/l



















against the negative inotropic effect of doxorubicin
Fig. 3 Negative inotropic action of 30 lmol/l doxorubicin in the
isolated mouse left atrium. Maximal protection by pre-incubation
with 7-monohydroxyethyl rutoside was 93%
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did not significantly influence the IC50 of doxorubicin in
the investigated cell lines (Table 1).
The antitumour activity of doxorubicin (8 mg/kg i.v.
twice weekly) in A2780 xenografts and OVCAR-3
(Fig. 5) xenografts in nude mice was not decreased
by 7-monohydroxyethylrutoside, administered 1 h before
doxorubicin in a dose schedule of 500 mg/kg i.p. 2 or
5 days per week [13].
Involvement of iron, inflammation and superoxide
anion radicals
Although the initial choice for selecting 7-monohydroxy-
ethylrutoside was among others based on its iron-chelating
properties, we recently obtained data, which question the
involvement of iron in oxidative stress mediated toxicity in
doxorubicin. We compared several well-known iron che-
lators (ICRF-187, 7-monohydroxyethylrutoside, deferox-
amine and pyridoxal isonicotinoyl hydrazone) and found
that only ICRF-187 and 7-monohydroxyethylrutoside pro-
tected the human lung adenocarcinoma cells A549 against
doxorubicin-induced oxidative stress while other chelators
did not [14].
Human umbilical cord vascular endothelial cells (HU-
VECs) were incubated with increasing concentrations of
doxorubicin (up to 25 lM) to investigate whether doxo-
rubicin could induce an inflammatory response in vitro. It
appeared that proliferating HUVECs were more sensitive
to doxorubicin (IC50 value of 60 ± 21 nM) than resting
cells (IC50 value of 4.0 ± 0.3 lM) [15]. Doxorubicin also
increased the adhesion of neutrophils, which was accom-
panied by overexpression of VCAM and E-selectin.
Treatment with 1 mM of 7-monohydroxyethylrutoside
prevented this overexpression. The increased levels of
adhesion molecules probably explain the stimulation of
neutrophil adhesion to the endothelial cells by 0.6 lM
doxorubicin. The flavonoid 7-monohydroxyethylrutoside
(1 mM) prevents the doxorubicin-stimulated neutrophil
adhesion [15].
This protective effect of the flavonoid against inflam-
mation was also observed recently in a study on ischaemia-
reperfusion in mice [16]. In this study, heart ischaemia was
induced for 30 min by ligating the left anterior descending
coronary artery. Afterwards, the ligature was removed and
reperfusion was allowed for 6 or 24 h. The protector 7-
monohydroxyethylrutoside was given i.p. (500 mg/kg) 1 h
before reperfusion and strongly attenuated myocardial
Fig. 4 Dose dependent
protection by 7-monoHER (i.p.)
on the ST-interval lengthening
of the ECG of mice treated with
doxorubicin. Image on the right
shows the X-ray of a mouse
with a transmitter to measure
the ECG via telemetry
Table 1 IC50 values of growth inhibition of various tumour cell lines by doxorubicin in absence and presence of 50 or 100 lM of 7-
monohydroxyetylrutoside
A2780 (·10–8 M) MCF-7 (·10–7 M) OVCAR-3 (·10–7 M)
Doxorubicin 2.05 ± 0.66 2.09 ± 0.75 3.28 ± 1.70
Doxorubicin + 50 lM 7-monoHER 2.57 ± 1.95 1.11 ± 0.04 4.29 ± 1.95
Doxorubicin + 100 lM 7-monoHER 2.00 ± 1.82 2.10 ± 0.22 5.67 ± 2.37
Data are expressed as mean ± SD of at least three independent experiments performed in triplicate
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neutrophil influx at both 6 and 24 h after reperfusion by
58% and 49%, respectively.
Clinical studies
A phase I human volunteer i.v. dose of monoHER escala-
tion study was performed in order to find the maximal
plasma concentration (Cmax) and the area under the plasma
concentration time curve (AUC¥) as observed in mice after
administration of the protecting dose of 500 mg/kg mono-
HER i.p. The study was performed as a single blind, ran-
domized trial in healthy volunteers (age between 19 and
56 years). At each dose level, six subjects received mono-
HER and three placebo. MonoHER was solubilized in
100 ml dextrose 5% and administered as an i.v. infusion in
10 min. The placebo consisted of 100 ml dextrose 5%. The
i.v. starting dose in human volunteers of monoHER was
100 mg/m2. Dose escalation by 100% of the preceding dose
took place after finishing each dose level until the protecting
pharmacokinetic values for Cmax and AUC
¥ (as observed in
mice after 500 mg/kg monoHER i.p.) were reached and/or
serious side effects were observed. The dose was escalated
up to 1500 mg/m2. The mean values of Cmax and AUC
¥
were 360 ± 69.3 lM and 6.8 ± 2.1 lmol min/ml, respec-
tively. These values were comparable to the Cmax and
AUC¥ observed under the protecting conditions in mice. No
serious side effects occurred during the entire study. From
this phase I study it could be concluded that 1,500 mg/m2 is
a feasible and safe dose to be evaluated in a phase II study to
investigate the protective properties of monoHER against
doxorubicin-induced cardiotoxicity in cancer patients [17].
This phase II study is currently conducted.
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